Scarless Laboratories, Inc.   Report issue

For profit Phase 2
Founded: Los Angeles CA United States (2004)

Organization Overview

First Clinical Trial
2019
NCT03880058
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Scarless Laboratories, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

sli-f06 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cicatrix (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1